Oncology Drugs - Tajikistan

Tajikistan

The projected revenue for the Oncology Drugs market in Tajikistan is set to reach US$8.37m in 2024.
It is expected to experience an annual growth rate of 7.88% from 2024 to 2029, resulting in a market volume of US$12.23m by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$103,900.00m in 2024.
Tajikistan's oncology drug market is witnessing a surge in demand due to the increasing prevalence of cancer in the country.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for oncology drugs in Tajikistan has been increasing in recent years.

Customer preferences: Patients in Tajikistan prefer to receive treatment for cancer using chemotherapy and radiation therapy. This preference is due to the low cost of these treatments compared to other options. Additionally, patients in Tajikistan tend to seek medical treatment at a later stage of their illness which can result in a higher demand for oncology drugs.

Trends in the market: The oncology drugs market in Tajikistan has been growing due to an increase in the incidence of cancer in the country. The market is dominated by multinational pharmaceutical companies that offer a wide range of oncology drugs. The market is also characterized by the availability of low-cost generic versions of oncology drugs.

Local special circumstances: The healthcare system in Tajikistan is underdeveloped, with limited access to medical facilities and trained healthcare professionals. This has resulted in a lack of awareness and education about cancer prevention and early detection. The lack of access to medical facilities also means that patients often seek treatment at a later stage in their illness, increasing the demand for oncology drugs.

Underlying macroeconomic factors: The economy of Tajikistan is heavily dependent on remittances from migrant workers, which account for a significant portion of the country's GDP. This has resulted in a low level of investment in the healthcare sector, which has affected the availability of medical facilities and trained healthcare professionals. The political instability in the region has also affected the healthcare system, with limited funding for research and development of new drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.